AN2 Therapeutics, Inc.
ANTX
$5.73
-$0.25-4.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.66% | 5.83% | -15.79% | 26.63% | 55.23% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.32% | -14.03% | 5.77% | -49.62% | 23.03% |
| Change in Net Operating Assets | 110.90% | -116.85% | 111.49% | 654.06% | -113.23% |
| Cash from Operations | 7.91% | -13.64% | 0.70% | 46.91% | 47.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -162.74% | -9.82% | 204.27% | -67.36% | -64.56% |
| Cash from Investing | -162.74% | -9.82% | 204.27% | -67.36% | -64.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 57,329.23% | -- | 108.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 57,329.23% | -- | 108.70% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -419.49% | 2,555.78% | 115.95% | -103.22% | -185.02% |